Upgrade to SI Premium - Free Trial

Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update

May 3, 2021 11:58 AM
Needham & Company analyst Chad Messer reiterated a Buy rating and $166.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles